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Abstract Objective: To test the
dose response effect of infused fish
oil (FO) rich in n-3 PUFAs on the
inflammatory response to endotoxin
(LPS) and on membrane incorpora-
tion of fatty acids in healthy subjects.
Design: Prospective, sequential
investigation comparing three differ-
ent FO doses. Subjects: Three
groups of male subjects aged
26.8 ± 3.2 years (BMI 22.5 ± 2.1).
Intervention: One of three FO doses
(Omegaven10%) as a slow infusion
before LPS: 0.5 g/kg 1 day before
LPS, 0.2 g/kg 1 day before, or
0.2 g/kg 2 h before. Measurements
and results: Temperature, hemody-
namic variables, indirect calorimetry
and blood samples (TNF-a, stress
hormones) were collected. After LPS
temperature, ACTH and TNF-a con-
centrations increased in the three
groups: the responses were
significantly blunted (p \ 0.0001)
compared with the control group of
the Pluess et al. trial. Cortisol was
unchanged. Lowest plasma ACTH,
TNF-a and temperature AUC values
were observed after a single 0.2 g/kg
dose of FO. EPA incorporation into
platelet membranes was dose-depen-
dent. Conclusions: Having
previously shown that the response to
LPS was reproducible, this study
shows that three FO doses blunted it
to various degrees. The 0.2 g/kg per-
fusion immediately before LPS was
the most efficient in blunting the
responses, suggesting LPS capture in
addition to the systemic and mem-
brane effects.
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Introduction
The interest in polyunsaturated fatty acid (PUFA) sup-
plementation has generated a large body of research
during the last decade. Among PUFA, the n-3 PUFAs
eicosapentaenoic acid (C20:5n-3, EPA) and docosahexa-
enoic acid (C22:6n-3, DHA), produced by plankton and
incorporated by fish, are the most biologically active. Fish
oil (FO) consumption increases the proportion of EPA
and DHA in the cell membrane phospholipids, particu-
larly in the monocytes and inflammatory cells. They
modulate the inflammatory processes by various mecha-
nisms, including downregulation of proinflammatory
eicosanoids and cytokines, adhesion molecules, as well as
genes involved in inflammation, by modifying phospho-
lipid membrane composition in the immune cells [1, 2]. In
addition, the n-3 PUFAs modulate key metabolic path-
ways, platelet functions and the excitability of
cardiomyocytes. Oral FO has been shown to exert bene-
ficial effects in patients with inflammatory diseases and
elevated cardiovascular risk [1]. While oral administra-
tion requires time to achieve these beneficial effects [3],
data in volunteers show that the intravenous administra-
tion achieves biological effects in a few hours [4]. The
development of intravenous lipid emulsions containing
FO enables exploring such properties in acute conditions.
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In a previous trial we showed that the intravenous
administration of two doses of 0.5 g/kg of FO in healthy
subjects resulted in a rapid incorporation of EPA and
DHA into the platelet membrane phospholipids [4]. This
was associated with a significant downregulation of the
neuroendocrine responses to endotoxin (LPS), as well as
of some components of the inflammatory response. In the
previous study, the 0.5 g/kg FO dose required a prolonged
infusion time (6 h). We hypothesized that smaller doses
of FO could exert similar effects with the advantage of a
reduction of infusion time and of total fat dose. Indeed in
acute medical settings, the two latter characteristics might
be an advantage when a rapid effect is required or the fat
tolerance is low (e.g., acute coronary conditions).
The present study aimed at comparing the effect of
various doses of intravenous FO in healthy subjects by
consecutive trials with three gradually decreasing FO
doses on membrane incorporation of n-3 PUFAs, as well
as on the physiological response to LPS.
Subjects and methods
After approval by the ethics committee of Lausanne’s
University School of Medicine, and with written informed
consent, healthy male subjects were enrolled in three
consecutive trials. A complete history (including a ques-
tionnaire on the frequency of fish intake) and physical
examination were performed before the study; a 12-lead
electrocardiogram was recorded. The inclusion criteria
were the following: age 18–35 years, being in good health
and taking no medications. Exclusion criteria were
smoking [10 cigarettes/day, alcohol consumption [1
glass wine or 1 beer/day, and a sea fish intake [ twice
weekly, or EPA/DHA supplementation.
Experimental design and treatment
Three consecutive studies were carried out testing various
regimens of intravenous FO in subjects submitted to the
same endotoxin challenge, using decreasing doses. The
trial used the same design as our previous randomized trial
comparing two doses of 0.5 g/kg FO versus placebo [4]:
• Day -1, 0.5 g/kg group: one 0.5 g/kg infusion of FO in
6 h, 24 h before the investigation day (n = 8).
• Day -1, 0.2 g/kg group: one 0.2 g/kg infusion of FO in
3 h, 24 h before the investigation day (n = 6).
• Day 0, 0.2 g/kg group: one 0.2 g/kg infusion of FO in
3 h, 2 h before the investigation (n = 7).
A purified FO solution was used in all groups
(Omegaven10%, provided by Fresenius Kabi AG, Bad
Homburg, Germany): 100 ml contain 10 g of FO,
providing 1.25–2.82 g of EPA; 1.44–3.09 g of DHA and
15–29.6 mg of D,L-a-tocopherol as antioxidant.
Infusion protocol
On the investigation day, subjects came at 8 a.m. to the
metabolic laboratory after an overnight fast. They were
requested to void, and the urine was discarded. Thereaf-
ter, they remained recumbent for the next 8 h. A venous
catheter was inserted into a vein of the left forearm for
LPS injection and labeled glucose infusion, and another
catheter was placed into a wrist vein of the right forearm
for blood sampling to avoid contamination of blood
samples by the infusion. The right hand was kept in a
thermo-stabilized box, heated at 56C to achieve partial
arterialization of venous blood.
Intervention
A dose of 2 ng/kg of endotoxin from E. Coli (USP,
Rockville, MD, batch no. 2, as a 200 ng/ml solution in
NaCl 0.9%) was given as an intravenous bolus at time T0
(injection time: 1 min).
Vital functions, including heart rate, respiratory rate,
rectal temperature (Hellige, Servomed), non-invasive
arterial blood pressure (Critikon, Dinamap), cardiac out-
put [thoracic bioimpedance (NCCOM3 cardiodynamic
monitor, BoMed, Irvine, CA] and oxygen saturation
(Ohmeda, Biox 3740 Pulse oximeter), were monitored.
Subjective symptoms such as muscle pain and headache,
nausea and vomiting were recorded.
Blood collection and analysis
Blood was drawn twice before the endotoxin challenge:
before the first infusion of FO and before the challenge.
Blood was drawn in tubes containing EDTA and plasma
immediately separated by low speed centrifugation (228
GIGA for 10 min at 4C). The plasma supernatant was
further centrifuged for 20 min at 1428 GIGA. Platelets
were then ‘‘washed’’ twice and centrifuged in a TRIS
solution. Thereafter, storage was done in formol at -80C
until analysis. For fatty acid (FA) determination in
platelet membranes, the lipid components, triglycerides,
phospholipids and cholesteryl esters were first separated
by two-dimensional thin layer chromatography. FAs in
phospholipids were then analyzed by gas chromatography
(Agilent, GC system, 6890 series; 6890A) [5]. During the
LPS challenge blood was sampled in all subjects every
30–60 min over the 8-h protocol to determine hormone
levels (cortisol, ACTH, catecholamines), inflammatory
markers (TNF-a, hsCRP), glucose, lactate, free FA and
triglyceride plasma levels. Blood samples were collected
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into heparinized tubes and centrifuged (3,000/min for 10
min at 4C) to separate plasma. Plasma was stored at -20
or -80C depending on the matrix until analysis. Cortisol
(kit from Diagnostic Products Corporation, Los Angeles,
CA) was determined by radioimmunoassay. ACTH was
determined by chemiluminescence assay (Nichols Insti-
tute Diagnostics, San Juan Capistrano, CA) (reference
range 10–60 ng/l). Plasma catecholamines were deter-
mined by HPLC with electrochemical detection.
ELISA in streptavidin-coated microtiter plates (Roche,
Mannheim, Germany) was used for in vitro determination
of TNF-a. High sensitivity C-reactive protein (hsCRP)
was measured by turbidimetry on a Hitachi 917(Roche)
and determined only at T0 and at the end of the trial.
Plasma glucose and lactate concentrations were mea-
sured enzymatically using a Yellow Spring Instrument
YSI 2300 STAT PLUS (Yellow Spring, OH). Plasma free
FA concentrations were measured with a colorimetric
method using a kit from Wako (Neuss, Germany).
Enzymatic determination of triglycerides in plasma was
performed with a TG PAP 150 kit (BioMe´rieux, Lyon,
France).
Indirect calorimetry was performed continuously
during the whole study (Datex, Deltatrac2, Helsinki,
Finland). Respiratory gases were collected with a canopy
to determine resting energy expenditure (REE) and net
substrate oxidation. REE was calculated using the equa-
tion of Livesey and Elia [6].
Statistical analysis data are presented as mean ± SD.
Areas under the curve (AUC) calculated using the trap-
ezoidal method were used to compare the overall effect
of FO between groups. The effect of time was explored
by means of two-factor repeated measures ANOVA and
n-3 PUFA dose (group = dose, group 9 time = inter-
vention). Post hoc comparisons were carried out by
Dunnett’s (effect of time versus baseline in each group)
or Scheffe’s test (between group comparisons at the same
time point). Membrane incorporation changes and AUC
were analyzed by non-parametric tests (Kruskal–Wallis).
The statistical package was: JMP Version 5.1., SAS
Institute Inc., Cary, NC. Significance was considered at
p B 0.05.
Results
The 23 subjects were aged 26.8 ± 3.2 years with a mean
body mass index (BMI) of 22.5 ± 2.1 kg/m2. Demo-
graphic variables were similar between the groups.
Platelet membrane incorporation
EPA incorporation in platelet phospholipids was observed
in all FO groups and was significantly higher in the group
receiving the largest FO dose (day 1, 0.5 g/kg) compared
with the two other groups (p \ 0.018) (Table 1). DHA
was also incorporated in platelet membranes, but the
changes were not significant.
Systemic effects of LPS
Significant increases in heart rate (?52% p \ 0.0001) and
cardiac output (?40%, p \ 0.0001) peaking at T240 after
LPS were observed in all subjects, while systolic, dia-
stolic, mean blood pressure and SpO2 did not change
significantly. REE variability was substantial and did not
reach steady state in the various parts of the study pre-
cluding statistical analysis because of marked shivering
(data not shown). Body temperature increased signifi-
cantly in all groups after LPS (Fig. 1). All subjects
complained of transient headache, nausea and muscle
pain. They were all discharged home symptom free, with
no medication.
Metabolism, cytokines and hormones
There were modest changes in plasma glucose and lactate
concentrations along the study from baseline, but these
were not significant.
LPS induced significant increases in plasma TNF-a,
norepinephrine, epinephrine and ACTH levels in all
groups (Table 2). Figure 2 shows that FO attenuated
several aspects of this response, with significant blunting
Table 1 EPA and DHA in platelet phospholipids before and after FO infusion (T0)
Group EPA (% molar) DHA (% molar)
Before FO T0 Change Before FO T0 Change
Day -1, 0.5 g/kg 0.41 ± 0.29 1.2 ± 0.15# ?0.79## 2.23 ± 0.40 2.61 ± 0.37 ?0.38
Day -1, 0.2 g/kg 0.32 ± 0.12 0.68 ± 0.16** ?0.36 1.97 ± 0.33 2.13 ± 0.55 ?0.16
Day 0, 0.2 g/kg 0.27 ± 0.25 0.67 ± 0.28* ?0.40 2.49 ± 0.38 2.90 ± 0.61 ?0.41
The incorporations of the previous trial delivering 2 9 0.5 g/kg FO
were higher (EPA ?1.4, DHA ?0.8% molar) [4]
Statistically significant within-group changes by two-way ANOVA
are indicated as * p = 0.05, ** p = 0.01, # p \ 0.001. Difference
between groups ## p = 0.018
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of the overall response of plasma TNF-a by AUC
(p \ 0.0001) in the day -1, 0.2 g/kg and day-0, 0.2 g/kg
groups compared to the day -1, 0.5 g/kg group.
The AUC of ACTH and the peak levels after LPS
were similarly lower in the day -1, 0.2 g/kg and day-0,
0.2 g/kg groups compared to the day -1, 0.5 g/kg group
(Fig. 2). Plasma norepinephrine did not differ among the
three groups (Table 1). The increase in plasma epineph-
rine AUC was blunted significantly only in the day -1,
0.2 g/kg group. Baseline hsCRP concentrations were
modestly higher in the day -1, 0.5 g/kg group (ns:
p = 0.14) and increased significantly only in the day -1,
0.2 g/kg group (mg/l), remaining a trend in both other
groups.
Discussion
In the present study, we tested the effects of three dif-
ferent decreasing regimens of intravenous FO on the cell
membrane phospholipid composition and on the physio-
logical response to LPS. The data were further compared
with those of our previous study, which was carried out
with the same design and which included a control group
[4]. The aim was to reduce both infusion time and the fat
load, while keeping the blunting effects of FO observed in
the first trial. We found that one or two 0.2-g/kg doses of
FO, administered within the 24 h before LPS challenge,
significantly influenced both membrane EPA content and
important aspects of the response to LPS.
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Fig. 1 Temperature over time in the three groups after LPS
injection: the increase was significantly blunted in all FO groups
(p = 0.0002) compared with the control group (dotted line) of
Pluess et al. [4]
Table 2 Evolution of the plasma TNF-a, hormone concentrations and hsCRP after the LPS challenge
T0 T60 T120 T240
TNF-a (\30 pg/ml)
Day -1, 0.5 g/kg (n = 8) 9.4 ± 7.3 129.5 ± 69.8 383.6 ± 155.5 91.0 ± 20.0
Day -1, 0.2 g/kg (n = 6) 6.9 ± 5.7 28.0 ± 8.8** 111.4 ± 25.7* 46.4 ± 9.9*
Day 0, 0.2 g/kg (n = 7) 21.2 ± 4.1 36.7 ± 6.5** 121.2 ± 48.8* 62.0 ± 15.0
T0 T120 T240 T360
Norepinephrine (reference range 0.47–2.94 nM/l)
Day -1, 0.5 g/kg 2.57 ± 0.84 3.86 ± 1.14 1.75 ± 0.59 1.44 ± 0.39
Day -1, 0.2 g/kg 2.13 ± 0.37 4.02 ± 1.45 2.01 ± 0.32 1.61 ± 0.29
Day 0, 0.2 g/kg 1.97 ± 0.21 1.93 ± 0.32 1.91 ± 0.41 1.46 ± 0.15
Epinephrine (reference range 0.02–0.44 nM/l)
Day -1, 0.5 g/kg 0.35 ± 0.08 0.34 ± 0.02 0.36 ± 0.07 0.31 ± 0.05
Day -1, 0.2 g/kg 0.14 ± 0.02 0.20 ± 0.04* 0.21 ± 0.03* 0.18 ± 0.03
Day 0, 0.2 g/kg 0.19 ± 0.03 0.24 ± 0.05 0.31 ± 0.09 0.20 ± 0.05
ACTH (reference range 10–60 ng/l)
Day -1, 0.5 g/kg 30.9 ± 7.3 129.8 ± 43.9 109.4 ± 40.1 20.4 ± 3.9
Day -1, 0.2 g/kg 6.2 ± 1.3*** 22.7 ± 3.9*** 21.8 ± 6.5** 3.0 ± 0.0**
Day 0, 0.2 g/kg 3.6 ± 0.6*** 16.9 ± 8.4*** 33.4 ± 21.3** 6.3 ± 2.3**
Cortisol (reference range 170–630 ng/l)
Day -1, 0.5 g/kg 226 ± 51 411 ± 123 458 ± 158 204 ± 96
Day -1, 0.2 g/kg 297 ± 55 420 ± 95 490 ± 125 215 ± 80
Day 0, 0.2 g/kg 195 ± 81 392 ± 145 515 ± 161 320 ± 235
hsCRP (reference range \0.11 mg/l)
Day -1, 0.5 g/kg 1.52 ± 2.83 – – 2.81 ± 3.53
Day -1, 0.2 g/kg 0.37 ± 0.12 – – 0.57 ± 0.16*
Day 0, 0.2 g/kg 0.74 ± 0.35 – – 0.81 ± 0.34
Statistics: All the hormone concentration changes over time were highly significant by two-way ANOVA, whereas the hsCRP change was
significant only in the day -1, 0.5 g/kg group. Post hoc tests between groups, * p = 0.05, ** p = 0.01, *** p \ 0.001
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Membrane incorporation of FO
Fatty acids are incorporated into cell membrane phos-
pholipids and play key roles in the physico-chemical
and functional characteristics of the cell membranes.
This in turn modifies important cell properties, including
regulation of the inflammatory response by modulating
ecosanoid synthesis and down-regulating cell signaling
and gene expression. The dietary FAs determine in part
the composition of membrane phospholipids [7]. Several
important membrane characteristics are influenced by
their fatty acid composition, as shown by experiments
analyzing the effects of various FAs in murine macro-
phage cultures [8]; incorporation of saturated FA into
macrophage membranes decreases their ability to
phagocytize and to adherence to surfaces, while the
phagocytic rates increase with an increasing degree of
unsaturation. This is caused by the changes in mem-
brane structure and fluidity, the latter being increased by
n-3 and reduced by n-6 PUFAs [9] compared with
saturated fatty acids [8], influencing multiple pathways
[10].
In this study, we observed that a single intravenous
infusion of FO significantly increased EPA content in
cell membranes. We observed a direct relation between
the dose of FO and the platelet membrane incorpora-
tion: the lowest incorporations were observed in the
two groups receiving 0.2 g/kg, while the highest uptake
of EPA (two times higher) was found in the group
receiving the largest FO dose (day -1, 0.5 g/kg;
p \ 0.0001). Furthermore, the EPA incorporation was
higher in our previous study using two doses of
0.5 g/kg FO, being 3.5 higher than in the groups
receiving the lowest dose of the actual study. Such a
finding suggests a direct dose effect.
The n-3 PUFA incorporation after oral FO supple-
ments is a rather slow process. In healthy subjects
receiving 6–9 g FO/day for 12 months, the incorporation
half-life of EPA in serum cholesteryl esters was calcu-
lated to be 4.8 days, while a plateau was reached after
4–8 weeks [7]. Recent data, including ours, show that the
intravenous route strongly accelerates the incorporation
into human cell membranes [4, 11]. In rats the bolus
administration of a novel MCT-FO solution achieves
incorporation of n-3 PUFAs into cell membranes after
only 60 min [12]. The data of the present study confirm
these preliminary data and report combined pharmaco-
logical and biological data.
Modulation of the physiological response to LPS
Several nutrients have been shown to modulate acute
inflammation, such as FO, antioxidant micronutrients and
glutamine. A large body of literature shows that FO
downregulates the inflammatory processes by complex
mechanisms including a decreased production of proin-
flammatory eicosanoid mediators (prostaglandins,
leukotrienes, thromboxanes), increased production of
DHA-derived resolvin D1 and protectin D1, which
attenuate neutrophil migration and attenuate NF-jB
activation and tissue damage in several disease models
[13], regulation of cell signaling of pathways involved in
immune responses and regulation of gene expression
involved in inflammation (transcription factors PPARs
and SREBPs) [9].
Experimental studies show that FO may influence the
response to LPS: FO increases survival in guinea pigs
submitted to lethal doses of LPS [14], improves
splanchnic and vital organ hemodynamics, and reduces
bacterial translocation [15]. This is also observed in
critically ill patients with acute inflammatory conditions
such as ARDS sepsis and surgery receiving FO with
parenteral nutrition [13].
In two previous studies in healthy subjects, FO was
found to reduce fever, as well as the neuro-endocrine and
inflammatory responses to LPS after 2–3 week of oral
supplementation, respectively [16], or much faster with
two large intravenous 0.5 g/kg FO doses [4]. In the
present study, lower doses or even a single dose achieved
similar changes. Interestingly, the blunting of the LPS
effects differed with the dose and the timing of admin-
istration, and was not directly proportional to the total FO
dose. Fever was attenuated in all groups compared to the
previous trial’s control group (Fig. 1). TNF-a response
was significantly blunted only in the two groups with the
lowest FO dose. The hypothalamo-pituitary adrenal
responses were blunted in all groups compared to the
control group of the previous trial [4]. Blunting of the
ACTH response was stronger in the 0.2 g/kg FO groups
compared to the 0.5 g/kg group (p = 0.0019). In the low
FO doses groups, the responses were not as clear cut for
the sympato-adrenal responses (epinephrine and
norepinephrine).
Dose effect
The study design, with consecutive trials, allowed
describing the relationship between different doses of FO
and biological responses. A direct effect of increasing
doses of FO was observed with membrane EPA incor-
poration, completing the results of our previous study [4],
suggesting a mass effect. Table 1 mentions the previous
trial’s higher incorporation after the double 0.5-g/kg dose.
Such a dose pattern was not observed with DHA due to
substantial inter-individual variability and the limited
power of the study.
The effect of FO on the response to LPS is complex.
The effect on fever was not influenced by the dose: the
blunting appears similar to that previously observed
(Fig. 1). Surprisingly, the suppressive effect on TNF-a
293
and ACTH was significantly more pronounced in the two
low-dose groups (0.2 g/kg) compared with the single or
double 0.5-g/kg doses of the previous trial (Fig. 2). We
have no clear explanation for this observation: timing,
dose of FO, membrane incorporation and genetic factors
seem to be the main causative factors. Fat emulsion
composition is another possible cause. Various types of
phospholipids, including phospholipids contained in any
parenteral nutrition fat emulsion, strongly inhibit LPS-
induced cytokine release by complex mechanisms [17],
including the direct binding of LPS. Even if the present
protocol, in absence of data, does not allow to reach
conclusions about direct LPS inhibition by fat emulsion,
such a mechanism is likely in the subjects receiving FO
immediately before LPS (day 0, 0.2 g/kg), as suggested
by the strongest blunting of LPS response in this group.
On the other hand, we have no clear explanation for the
large ACTH and TNF-a blunting observed in the day -1,
0.2 g/kg group in which FO was infused 24 h before the
LPS challenge.
Limitations
The study has limitations. The number of subjects per
group was low, reducing the power of the statistical
analysis. The biological effects of FO have substantial
inter-individual variability with a potential for outliers
related to factors including genetics: this might be
amplified by the small numbers, although the data do not
show real outliers.
The limited power probably explains why the DHA
membrane incorporation was not significant, contrasting
with that of EPA, which had greater changes with a
lower variability. AUCs were calculated for every
variable, which is an appropriate method for a kinetic
study with the advantage of reducing the negative
impact of the small numbers with repeated determina-
tions. We determined membrane FA composition only
in platelets and not in other immune cells responsible
for the inflammatory response. A recent study per-
formed in healthy volunteers receiving intravenous FO
showed similar incorporation dynamics in platelets,
monocytes and erythrocytes [11], although with differ-
ent rates of incorporation. This suggests that monocyte
membranes in our healthy volunteers were also influ-
enced by the FO infusion. Further, we did not assess
thromboxanes and leukotrienes, important targets of FO
administration, which limits the interpretation of our
results.
Finally, to limit LPS administration in numerous
control groups, a highly disagreeable procedure that
incurs laboratory costs, we proceeded by consecutive
trials. Such a design is commonly used in pharmacolog-
ical studies to reduce the number of experiments. This
trial was not designed to determine the lowest dose of
intravenous FO achieving a blunting effect, only one that
could be used in clinical settings.
Conclusion
Altogether the results show that a small dose of par-
enteral FO administered just before a LPS challenge
produces a significant EPA membrane incorporation
already 6 h after the injection and attenuates the phys-
iological response to LPS. This was also observed with
a single 0.2-g/kg dose. These results open important
perspectives in pre-conditioning of patients before
interventions known to elicit strong inflammatory
responses.
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